# A Study in Advanced Cancer

> **NCT01226485** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 84 (actual)

## Conditions studied

- Advanced Cancer

## Interventions

- **DRUG:** Taladegib

## Key facts

- **NCT ID:** NCT01226485
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-09
- **Primary completion:** 2015-01
- **Final completion:** 2017-10
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2019-09-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01226485

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01226485, "A Study in Advanced Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01226485. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*